Core Insights - BJ's Restaurants reported revenue of $355.4 million for the quarter ended December 2025, reflecting a 3.2% increase year-over-year [1] - The company's EPS was $0.66, up from $0.47 in the same quarter last year, indicating a strong performance [1] - Revenue exceeded the Zacks Consensus Estimate of $351.89 million by 1%, while EPS surpassed the consensus estimate of $0.60 by 10% [1] Financial Performance Metrics - Comparable restaurant sales increased by 2.6%, outperforming the average estimate of 1.9% from four analysts [4] - The number of restaurants remained stable at 219, matching the average estimate from analysts [4] - Restaurant operating weeks totaled 2,847, consistent with the average estimate based on three analysts [4] Stock Performance - Shares of BJ's Restaurants have declined by 4% over the past month, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [3]

Core Insights - Jack In The Box reported a revenue of $349.52 million for the quarter ended December 2025, reflecting a year-over-year decline of 25.6% and an EPS of $1.00 compared to $1.92 a year ago, with a revenue surprise of +1.64% over the Zacks Consensus Estimate [1] Financial Performance - The reported revenue of $349.52 million exceeded the Zacks Consensus Estimate of $343.87 million by +1.64% [1] - The EPS of $1.00 was below the consensus estimate of $1.10, resulting in an EPS surprise of -8.81% [1] Key Metrics - Jack In The Box shares returned +3.2% over the past month, while the Zacks S&P 500 composite experienced a -1.3% change [3] - The company holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Restaurant Counts and Sales - Total restaurant counts at the end of the period were 2,128, surpassing the four-analyst average estimate of 2,106 [4] - Franchised restaurant counts were 1,979, compared to the average estimate of 1,956 [4] - Company restaurant counts were 149, slightly below the average estimate of 150 [4] - Same-store sales for the system declined by -6.7%, worse than the average estimate of -5.2% [4] - Company same-store sales decreased by -4.7%, also better than the average estimate of -5.1% [4] Revenue Breakdown - Franchise rental revenues were reported at $97.39 million, below the average estimate of $98.63 million, marking a -16.4% year-over-year change [4] - Franchise contributions for advertising and other services were $61.35 million, compared to the estimated $64.78 million, representing a -20.8% change year-over-year [4] - Total franchise revenues (rental + royalties + contributions) were $217.61 million, below the average estimate of $224.75 million, reflecting an -18.9% year-over-year change [4] - Franchise royalties and other revenues were $58.88 million, compared to the estimated $61.34 million, indicating a -20.5% change year-over-year [4] - Company restaurant sales were $131.91 million, below the average estimate of $144.15 million, with a year-over-year decline of -34.5% [4]

Core Insights - Community Healthcare Trust (CHCT) reported revenue of $30.95 million for the quarter ended December 2025, reflecting a 5.6% increase year-over-year, but fell short of the Zacks Consensus Estimate of $31.58 million by 1.99% [1] - The earnings per share (EPS) for the quarter was $0.55, significantly higher than $0.04 in the same quarter last year, but below the consensus estimate of $0.57, resulting in an EPS surprise of -2.66% [1] Revenue Breakdown - Rental income was reported at $30.68 million, which is a 5.9% increase compared to the year-ago quarter, but below the average estimate of $31.2 million from two analysts [4] - Other operating interest, net, was reported at $0.27 million, which is a decrease of 15.2% year-over-year and also below the average estimate of $0.29 million from two analysts [4] Stock Performance - Over the past month, shares of Community Healthcare Trust have returned +3.5%, outperforming the Zacks S&P 500 composite, which saw a -1.4% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Group 1 - The core viewpoint is that Xchange Tec.Inc (XHG.OQ) has experienced a volatile stock price with a cumulative decline of 1.08% over the past seven trading days, despite a significant revenue growth forecast for fiscal year 2025 [1][2][3] Group 2 - In the recent trading period from February 5 to February 11, 2026, Xchange Tec.Inc's stock price fluctuated, with a total drop of 1.08% and a price range fluctuation of 13.55%. The stock saw a notable drop of 7.53% on February 5, followed by a rebound of 9.53% on February 6, and further declines of 7.11% on February 9, with slight recoveries on February 10 and 11 [2] - The latest stock price as of February 12 is $0.92, remaining unchanged from the previous trading day, with a total trading volume of approximately $14,000, indicating low market activity [2] Group 3 - According to the fiscal year 2025 annual report released on January 14, 2026, Xchange Tec.Inc reported a revenue of $50.6379 million, reflecting a year-on-year growth of 26.55%. However, the company recorded a net loss attributable to shareholders of $103.7545 million, resulting in a net profit margin of -204.90% and a gross profit margin of only 2.19% [3] - The company's debt-to-asset ratio is alarmingly high at 1368.62%, indicating a persistent state of financial loss [3]

Core Insights - AbbVie reported revenue of $16.62 billion for the quarter ended December 2025, reflecting a 10% increase year-over-year and a surprise of +1.58% over the Zacks Consensus Estimate of $16.36 billion [1] - The earnings per share (EPS) for the quarter was $2.71, up from $2.16 in the same quarter last year, with an EPS surprise of +2.02% compared to the consensus estimate of $2.66 [1] Revenue Performance by Product - Humira's net revenue in the US was $897 million, significantly below the average estimate of $574.85 million, representing a year-over-year decline of -28% [4] - Internationally, Humira generated $349 million, slightly below the estimated $374.4 million, marking a -20% change year-over-year [4] - Oncology product Elahere reported $182 million, which was below the average estimate of $191.62 million but showed a +23% increase year-over-year [4] - Qulipta's international revenue reached $43 million, exceeding the estimate of $39.74 million, with a remarkable +186.7% year-over-year growth [4] - The Juvederm Collection generated $249 million, below the estimate of $272.17 million, reflecting a -10.8% year-over-year decline [4] - Vraylar's total revenue was $1.02 billion, surpassing the estimate of $994.67 million, with a +10.6% year-over-year increase [4] - Imbruvica's revenue was $671 million, below the average estimate of $714.9 million, showing a -20.9% year-over-year decline [4] - Eye Care products generated $580 million, slightly above the estimate of $568.88 million, with a -10.2% year-over-year change [4] - Botox Therapeutic revenue was $990 million, close to the estimate of $995.91 million, reflecting a +13.4% year-over-year increase [4] - Aesthetics revenue totaled $1.29 billion, slightly above the estimate of $1.28 billion, with a -0.9% year-over-year change [4] - Venclexta generated $710 million, below the estimate of $725.34 million, with an +8.4% year-over-year increase [4] - Neuroscience product Vyalev reported $183 million, exceeding the estimate of $170.15 million [4] Stock Performance - AbbVie shares returned +0.8% over the past month, compared to a +0.9% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - PepsiCo reported revenue of $29.34 billion for the quarter ended December 2025, reflecting a 5.6% increase year-over-year and surpassing the Zacks Consensus Estimate of $29 billion by 1.18% [1] - The company's EPS for the quarter was $2.26, up from $1.96 in the same quarter last year, also exceeding the consensus estimate of $2.24 by 1.09% [1] Revenue Performance by Segment - International Beverages Franchise (IB Franchise) generated net revenue of $1.58 billion, slightly above the estimated $1.55 billion [4] - EMEA (Europe, Middle East and Africa) reported net revenue of $6.08 billion, exceeding the average estimate of $6.03 billion [4] - PepsiCo Beverages North America (PBNA) achieved net revenue of $8.2 billion, surpassing the estimate of $8.14 billion and showing a year-over-year increase of 3.7% [4] - PepsiCo Foods North America (PFNA) reported net revenue of $8.31 billion, significantly higher than the estimated $8.22 billion, with a remarkable year-over-year change of 851.1% [4] - Latin America Foods (LatAm Foods) generated net revenue of $3.68 billion, slightly above the estimate of $3.58 billion, but reflecting a year-over-year decline of 0.2% [4] - Asia Pacific Foods reported net revenue of $1.49 billion, exceeding the estimated $1.46 billion [4] Core Operating Profit Analysis - Core Operating Profit for PFNA was $1.91 billion, matching the average estimate [4] - Core Operating Profit for PBNA was $721 million, slightly below the estimated $729.64 million [4] - Core Operating Profit for IB Franchise was $528 million, below the average estimate of $544.86 million [4] - Corporate unallocated Core Operating Profit was reported at -$738 million, worse than the estimated -$723.95 million [4] - Core Operating Profit for LatAm Foods was $725 million, slightly above the average estimate of $722.5 million [4] - Core Operating Profit for Asia Pacific Foods was $54 million, below the estimated $70.19 million [4] Stock Performance - PepsiCo shares have returned +10.9% over the past month, outperforming the Zacks S&P 500 composite's +1.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Willis Towers Watson (WTW) reported a revenue of $2.94 billion for the quarter ended December 2025, reflecting a decrease of 3.3% year-over-year, while EPS was $8.12, slightly down from $8.13 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $2.86 billion by 2.51%, and the EPS also surpassed the consensus estimate of $7.92 by 2.47% [1] Revenue Breakdown - Health, Wealth and Career segment revenue was $1.65 billion, slightly above the average estimate of $1.64 billion, but down 11.1% year-over-year [4] - Reimbursable expenses and other revenue reached $31 million, exceeding the estimated $26.16 million, but showed a significant decline of 24.4% compared to the previous year [4] - Total segment revenue was reported at $2.9 billion, surpassing the average estimate of $2.84 billion, with a year-over-year decline of 4.4% [4] - Risk and Broking segment revenue was $1.25 billion, exceeding the average estimate of $1.19 billion, and showed a year-over-year increase of 9.8% [4] Operating Income - Segment Operating Income for Risk and Broking was $435 million, higher than the estimated $408.38 million [4] - Segment Operating Income for Health, Wealth and Career was reported at $729 million, slightly above the average estimate of $719.31 million [4] Stock Performance - Over the past month, shares of Willis Towers Watson have returned -5.4%, contrasting with the Zacks S&P 500 composite's +1.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Pentair plc reported revenue of $1.02 billion for Q4 2025, marking a year-over-year increase of 4.9% and exceeding the Zacks Consensus Estimate by 1.6% [1] - The earnings per share (EPS) for the same quarter was $1.18, up from $1.08 a year ago, with an EPS surprise of 1.14% over the consensus estimate of $1.17 [1] Revenue Growth Metrics - Core revenue growth for Pentair was 3.7%, surpassing the average estimate of 3.3% from five analysts [4] - Core revenue growth in the Pool segment was 8.9%, significantly higher than the 4% estimated by four analysts [4] - Core revenue growth in the Flow segment was 4%, slightly above the 3.9% average estimate from four analysts [4] - Core revenue growth in the Water Solutions segment declined by 3.7%, contrasting with the 1.3% average estimate from four analysts [4] Net Sales Performance - Net sales in the Pool segment reached $393.4 million, exceeding the average estimate of $372.66 million and reflecting a year-over-year increase of 11.2% [4] - Net sales in the Flow segment were $394.4 million, slightly above the estimated $389.44 million, representing a 9.3% year-over-year increase [4] - Net sales in the Corporate and other segment were $0.4 million, below the estimated $0.57 million, showing a decline of 33.3% year-over-year [4] - Net sales in the Water Solutions segment totaled $232.3 million, falling short of the $240.66 million estimate, with a year-over-year decrease of 9.9% [4] Segment Income Analysis - Segment income for the Flow segment was $90.1 million, exceeding the average estimate of $84.65 million [4] - Segment loss for Corporate and other was $-25.2 million, worse than the estimated $-20.03 million [4] - Segment income for the Pool segment was $132.2 million, above the average estimate of $126.69 million [4] - Segment income for Water Solutions was $54.6 million, slightly below the average estimate of $59.46 million [4] Stock Performance - Pentair's shares have returned +2.8% over the past month, outperforming the Zacks S&P 500 composite's +1.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Hexcel (HXL) reported revenue of $491.3 million for the quarter ended December 2025, marking a year-over-year increase of 3.7% and exceeding the Zacks Consensus Estimate by 2.7% [1] - The earnings per share (EPS) for the same period was $0.52, consistent with the previous year and surpassing the consensus estimate by 4.31% [1] Financial Performance - Net Sales in Commercial Aerospace - Composite Materials reached $257.9 million, exceeding the average estimate of $246.71 million, with a year-over-year increase of 10.3% [4] - Net Sales in Defense, Space & Other - Composite Materials were $136.6 million, above the average estimate of $129.02 million, reflecting a year-over-year growth of 24% [4] - Net Sales in Commercial Aerospace - Engineered Products totaled $41.6 million, below the estimated $46.92 million, showing a decline of 6.5% year-over-year [4] - Total Net Sales in Composite Materials amounted to $415.1 million, surpassing the average estimate of $375.72 million, with a year-over-year increase of 5% [4] - Operating income for Composite Materials was reported at $85.2 million, significantly higher than the estimated $39.49 million [4] Stock Performance - Hexcel's shares have returned +7.7% over the past month, outperforming the Zacks S&P 500 composite's +0.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Ameris Bancorp reported revenue of $308.11 million for Q4 2025, a 6% year-over-year increase, with an EPS of $1.59 compared to $1.38 a year ago [1] - The revenue fell slightly short of the Zacks Consensus Estimate of $308.67 million, resulting in a surprise of -0.18%, while the EPS exceeded the consensus estimate of $1.56 by 2.25% [1] Financial Performance Metrics - Net interest margin (TE) was reported at 3.9%, surpassing the average estimate of 3.8% from three analysts [4] - The efficiency ratio stood at 46.6%, better than the average estimate of 50.5% from three analysts [4] - Book value per share at period end was $59.92, slightly above the estimated $59.68 [4] - Net charge-offs as a percentage of average loans (annualized) were 0.3%, higher than the average estimate of 0.2% [4] - Total non-performing assets amounted to $120.47 million, exceeding the average estimate of $114.45 million [4] - Average balances of total earning assets were $25.4 billion, close to the estimated $25.37 billion [4] - Net interest income (TE) was reported at $246.29 million, above the average estimate of $239.71 million [4] - Total non-interest income was $61.83 million, below the average estimate of $68.95 million [4] - Net interest income was $245.31 million, exceeding the average estimate of $239.84 million [4] Stock Performance - Shares of Ameris Bancorp have returned +7.3% over the past month, outperforming the Zacks S&P 500 composite's +0.8% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]